natgillin/translations-raw huggingface dataset:
carbamazepin, phenytoin – bruges til epilepsi,
carbamazepine, phenytoin – used for epilepsy,
carbamazepin, phenytoin, phenobarbital
carbamazepine, phenytoin, phenobarbital
carbamazepin, phenytoin, phenobarbital, lamotrigin (anvendes mod epilepsi)
carbamazepine, phenytoin, phenobarbital, lamotrigine (antiepileptics)
carbamazepin, S-mephenytoin, phenytoin, lægemidler, der anvendes til at forebygge krampeanfald
carbamazepine, S-mephenytoin, phenytoin, medicines used to prevent seizures
carbamazepin,der anvendes mod bestemte former for epilepsi
carbamazepine, a medicine to treat some forms of epilepsy,
Carbamazepin- og phenobarbital-
Carbamazepine and phenobarbital
Carbamazepin- og phenobarbital- niveauerne bør overvåges ved samtidig administration med lopinavir/ritonavir.
Carbamazepine and phenobarbital levels should be monitored when co- administering with lopinavir/ritonavir.
Carbamazepin-10,11-epoxid: AUC: ↓ 35 %
Carbamazepine-10,11-epoxide: AUC: ↓ 35
Carbamazepin/dolutegravir
Carbamazepine/Dolutegravir
Carbamazepin/efavirenz (400 mg q.d./600 mg q.d.)
Carbamazepine/Efavirenz (400 mg q.d./600 mg q.d.)
Carbamazepin/efavirenz (400 mg én gang dagligt/600 mg én gang dagligt)
Carbamazepine/Efavirenz (400 mg once daily/600 mg once daily)
Carbamazepin: AUC: ↑ 43 %
Carbamazepine: AUC: ↑ 43
carbamazepin: et lægemiddel, der bruges til at behandle epilepsi, euforiske/depressive stadier og visse smertetilstande
carbamazepine: a medicine to treat epilepsy, euphoric/depressive stages and certain pain conditions.
carbamazepine een geneesmiddel gebruikt om bepaalde vormen van epilepsie te behandelen,
carbamazepine a medicine to treat some forms of epilepsy,
carbamoyl phosphate-synthase-1 deficiency
carbamoyl phosphate-synthase-1 deficiency;
Carbidopa metaboliseres til to hovedmetabolitter, der udskilles i urinen som glukoronider og ikke- konjugerede komponenter.
Carbidopa is metabolized to two main metabolites which are excreted in the urine as glucuronides and unconjugated compounds.
Carbidopa og benserazid er perifere DDC-hæmmere, der reducerer den perifere metabolisme af levodopa til dopamin, ved at gøre mere levodopa tilgængelig for hjernen.
Carbidopa and benserazide are peripheral DDC inhibitors which reduce the peripheral metabolism of levodopa to dopamine, and thus, more levodopa is available to the brain.
Carbidopa og entacapon forbedrer levadopas antiparkinson-virkning.
Carbidopa and entacapone improve the antiparkinson effects of levodopa.
Carbomer ............................................................................................................................................4 mg
Carbomer ...........................................................................................................................................4 mg.
Carbomer 971 P NF 2,0 mg
Carbomer 971 P NF 2.0 mg
Carbomer 980 Dinatriumphosphat, vandfri Natriumhydroxid
Carbomer 980 disodium phosphate anhydrous Sodium hydroxide
Carbomer Methylparahydroxybenzoat (E218) Phenoxyethanol
Carbomer Methylparahydroxybenzoate (E218) Phenoxyethanol
Carbomer Natriumchlorid
Carbomer Sodium chloride
Carbomer...........................................................................................................................................
Carbomer.........................................................................................................................................
Carbomer............................................................................................................................................4 mg
Carbomer...........................................................................................................................................4 mg.
Carbomer………………………………………………………………………................................4 mg Se afsnit 6.1 for en fuldstændig fortegnelse over hjælpestoffer.
For the full list of excipients, see section 6.1.
carbonat
decreased
carbonat
Grand mal seizure
carbonat
Pruritus Ecchymosis
Carboplatin (AUC4, dag 1) og gemcitabin (1.000 mg/m2 på dag 1 og 8) samtidig med Avastin (15 mg/kg, dag 1) hver 3. uge i 6 og op til 10 behandlingsserier, efterfulgt af Avastin (15 mg/kg hver 3. uge) som monoterapi indtil sygdomsprogresssion eller uacceptabel toksicitet.
Carboplatin (AUC4, Day 1) and gemcitabine (1000 mg/m2 on Days 1 and 8) and concurrent Avastin (15 mg/kg Day 1) every 3 weeks for 6 and up to 10 cycles followed by Avastin (15 mg/kg every 3 weeks) alone until disease progression or unacceptable toxicity
Carboplatin (AUC4, dag 1) og gemcitabin (1.000 mg/m2 på dag 1 og 8) samtidig med placebo hver 3. uge i 6 og op til 10 behandlingsserier, efterfulgt af placebo (hver 3. uge) som monoterapi indtil sygdomsprogresssion eller uacceptabel toksicitet.
Carboplatin (AUC4, Day 1) and gemcitabine (1000 mg/m2 on Days 1 and 8) and concurrent placebo every 3 weeks for 6 and up to 10 cycles followed by placebo (every 3 weeks) alone until disease progression or unacceptable toxicity
Carboplatin/ Paclitaxel +
Paclitaxel +
Carboxydabrafenib udskilles i galden og urinen.
Carboxy- dabrafenib is excreted in bile and urine.
Carcinogenecitetsundersøgelser på hanmus samt han- og hunrotter var negative.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
Carcinogenese, mutagenese, nedsat frugtbarhed
Carcinogenesis, mutagenesis, impairment of fertility
Carcinoma hepatocellulære er en alvorlig komplikation af hepatitis B virusinfektion.
Hepatocellular carcinoma is a serious complication of hepatitis B virus infection.
Cardalis 10 mg/80 mg tyggetabletter
10 mg/80 mg chewable tablets
Cardalis 10 mg/80 mg tyggetabletter til hund Benazepril hydroklorid 10 mg, spironolakton 80 mg (benazepril HCl/spironolactone)
Cardalis 10 mg/80 mg chewable tablets for dogs Benazepril hydrochloride 10 mg, spironolactone 80 mg
Cardalis 2,5 mg/20 mg tyggetabletter
Cardalis 2.5 mg/20 mg chewable tablets
Cardalis 2,5 mg/20 mg tyggetabletter til hund Benazepril hydroklorid 2,5 mg, spironolakton 20 mg (benazepril HCl/spironolactone)
Cardalis 2.5 mg/20 mg chewable tablets for dogs Benazepril hydrochloride 2.5 mg, spironolactone 20 mg
Cardalis 5 mg/40 mg tyggetabletter
Cardalis 5 mg/40 mg chewable tablets
Cardalis 5 mg/40 mg tyggetabletter til hund Benazepril hydroklorid 5 mg, spironolakton 40 mg (benazepril HCl/spironolactone)
Cardalis 5 mg/40 mg chewable tablets for dogs Benazepril hydrochloride 5 mg, spironolactone 40 mg
Cardalis bør ikke anvendes i tilfælde af aortastenose eller pulmonal stenose (forsnævring af aorta eller pulmonale blodkar), som påvirker hjertets output af blod.
Cardalis must not be used in cases of aortic or pulmonary stenosis (narrowing of the aorta or pulmonary blood vessels) affecting the heart’s blood output.
Cardalis må ikke anvendes hos hunde med Addisons sygdom eller hypoadrenokorticisme (en sygdom, hvor binyren fremstiller for få hormoner), hyperkaliæmi (øget kaliumindhold i blodet) eller hyponatriæmi (mindsket natriumindhold i blodet).
Cardalis must not be used in dogs with Addison’s disease or hypoadrenocorticism (a condition where the adrenal gland does not produce sufficient amounts of hormones), hyperkalaemia (increased blood potassium levels) or hyponatraemia (reduced blood sodium levels).
Cardalis tyggetabletter bør administreres til hunden én gang dagligt i en dosering af 0,25 mg/kg legemsvægt (lgm.) benazepril hydroklorid (HCl) og 2 mg/kg lgm. spironolakton jf. doseringskemaet nedenfor.
Cardalis chewable tablets should be administered to the dog once a day using a dosage of 0.25 mg/kg bodyweight benazepril hydrochloride (HCl) and 2 mg/kg bodyweight (bw) spironolactone, according to the following dosage table.
Cardalis tyggetabletter bør administreres til hunden én gang dagligt i en dosering af 0,25 mg/kg legemsvægt (lgm.) benazepril hydroklorid og 2 mg/kg lgm. spironolakton jf. doseringskemaet nedenfor.
Cardalis chewable tablets should be administered to the dog once a day using a dosage of 0.25 mg/kg bodyweight (bw) benazepril hydrochloride (HCl) and 2 mg/kg bodyweight spironolactone, according to the following dosage table.
Cardiomyopati
Cardiomyopathy
Care Ltd.
Health Care Ltd.
Care Ltd.
Transdermal
Carfilzomib hæmmer ikke human UGT2B7, men hæmmer human UGT1A1 med en IC50 på 5,5 µM. Ikke desto mindre er risikoen for klinisk relevante interaktioner med substrater for OATP1B1 og UGT1A1 sandsynligvis lav i betragtning af den hurtige eliminering af carfilzomib, herunder især det hurtige fald i den systemiske koncentration 5 minutter efter infusionens afslutning.
Carfilzomib does not inhibit human UGT2B7 but inhibits human UGT1A1 with an IC50 of 5.5 µM. Nonetheless, considering the fast elimination of carfilzomib, notably a rapid decline in systemic concentration 5 minutes after the end of infusion, the risk of clinically relevant interactions with substrates of OATP1B1 and UGT1A1 is probably low.
Carfilzomib hæmmer OATP1B1 in vitro med en IC50 = 2,01 µM. Det vides derimod ikke, hvorvidt carfilzomib kan hæmme andre transportører (OATP1B3, OAT1, OAT3, OCT2 og BSEP) ved systemiske koncentrationer.
In vitro, carfilzomib inhibits OATP1B1 with an IC50 = 2.01 µM whereas it is unknown whether carfilzomib may or not inhibit other transporters OATP1B3, OAT1, OAT3, OCT2 and BSEP, at the systemic level.
Carfilzomib metaboliseres primært gennem peptidase- og epoxidhydrolase-aktivitet, og carfilzomibs farmakokinetiske profil vil derfor sandsynligvis ikke blive påvirket af samtidig administration af CYP-hæmmere og -induktorer.
Carfilzomib is primarily metabolised via peptidase and epoxide hydrolase activities, and as a result, the pharmacokinetic profile of carfilzomib is unlikely to be affected by concomitant administration of cytochrome P450 inhibitors and inducers.
Carfilzomib udviste antiproliferativ og proapoptotisk aktivitet i prækliniske modeller i hæmatologiske tumorer.
Carfilzomib had antiproliferative and proapoptotic activities in preclinical models in haematologic tumours.
Carfilzomib var ikke mutagent i en in vitro bakteriel tilbagemutationstest (Ames’ test) og var ikke klastogent i en in vivo mikronukleusanalyse i knoglemarv fra mus.
Carfilzomib was not mutagenic in the in vitro bacterial reverse mutation (Ames) test and was not clastogenic in the in vivo mouse bone marrow micronucleus assay.
Carfilzomibs mulige virkninger på hjertefunktionen blev vurderet ved en central, blindet vurdering af tre ekg-optagelser fra hver af 154 patienter med fremskredne maligniteter, herunder multipelt myolom.
An evaluation of possible effects of carfilzomib on cardiac function was performed by analyzing, via central blind reading, triplicate ECG in 154 subjects with advanced malignancies, including multiple myeloma.
Cargluminsyre er mere resistent end N-acetylglutamat overfor hydrolyse med aminoacylase tilstede i cytosolen.
Carglumic acid is more resistant than N-acetylglutamate to hydrolysis by aminoacylase present in the cytosol.
Cargluminsyre-responstest
Carglumic acid responsiveness test
Carisoprodo
Carisoprodol
Carmellosecalcium Hydroxypropylcellulose Lactosemonohydrat Magnesiumstearat
Carmellose calcium Hydroxypropylcellulose Lactose monohydrate Magnesium stearate
Carmellosecalcium Hydroxypropylcellulose Lactosemonohydrat Magnesiumstearat
Carmellose calcium HydroxypropylcelluloseLactose monohydrate Magnesium stearate
Carmellosenatrium, mannitol, natriumdihydrogenphosphatmonohydrat, natriumhydroxid
Carmellose sodium, mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide
Carnaubavoks,
Carnauba wax
Carrigaline County Cork Irland
Carrigaline County Cork Ireland
Carrigaline County Cork Irland
Carrigaline County Cork Ireland.
Carrigaline, County Cork, Irland
Carrigaline, County Cork, Ireland
Carrigtohill County Cork Irland
Carrigtohill County Cork Ireland
Carvedilol Metoprolol Timolol
Carvedilol
Case by case fordel/risiko-vurdering hos børn
Case by case benefit/risk assessment in children
Case by case fordel/risiko-vurdering hos børn:
Case by case benefit/risk assessment in children
Case by case-fordel/risikovurdering hos børn:
Case by case benefit/risk assessment in children:
Case-kontrol- studie (USA)
Case-control study (US)
Casein hydrolysat Kollagen hydrolysat Dikaliumphosphat
Casein hydrolysate Collagen hydrolysate Dipotassium phosphate
Caspofungin Accord 50 mg pulver til koncentrat til infusionsvæske, opløsning
Caspofungin Accord 50 mg powder for concentrate for solution for infusion
Caspofungin Accord 50 mg pulver til koncentrat til infusionsvæske, opløsning caspofungin
Caspofungin Accord 50 mg powder for concentrate for solution for infusion caspofungin
Caspofungin Accord 50 mg pulver til koncentrat til infusionsvæske, opløsning Hvert hætteglas indeholder 50 mg caspofungin (som acetat).
Caspofungin Accord 50 mg powder for concentrate for solution for infusion Each vial contains 50 mg caspofungin (as acetate).
Caspofungin Accord 70 mg pulver til koncentrat til infusionsvæske, opløsning
Caspofungin Accord 70 mg powder for concentrate for solution for infusion
Caspofungin Accord 70 mg pulver til koncentrat til infusionsvæske, opløsning caspofungin
Caspofungin Accord 70 mg powder for concentrate for solution for infusion caspofungin
Caspofungin Accord anvendes til at behandle følgende infektioner hos børn, teenagere og voksne: alvorlige svampeinfektioner i væv eller organer (kaldet "invasiv candidiasis").
Caspofungin Accord is used to treat the following infections in children, adolescents and adults: serious fungal infections in your tissues or organs (called ‘invasive candidiasis’).
Caspofungin Accord er et "generisk lægemiddel".
Caspofungin Accord is a ‘generic medicine’.
Caspofungin Accord er formuleret med henblik på at kunne give den fulde dosis, der er angivet på hætteglassets etiket (50 mg), når 10 ml trækkes op af hætteglasset.
c Caspofungin Accord is formulated to provide the full labeled vial dose (50 mg) when 10 mL is withdrawn from the vial.
Caspofungin Accord er formuleret med henblik på at kunne give den fulde dosis, der er angivet på hætteglassets etiket (70 mg), når 10 ml trækkes op af hætteglasset.
Caspofungin Accord is formulated to provide the full labeled vial dose (70 mg) when 10 mL is withdrawn from the vial.
Caspofungin Accord er formuleret med henblik på at kunne give den fulde dosis, der er angivet på hætteglassets etiket (70 mg), når 10 ml trækkes op af hætteglasset.
Caspofungin Accord is formulated to provide the full labelled vial dose (70 mg) when 10 mL is withdrawn from the vial.
Caspofungin Accord er formuleret mhp at kunne give den fulde dosis, der er angivet på hætteglassets etiket (50 mg), når 10 ml trækkes op af hætteglasset.
Caspofungin Accord is formulated to provide the full labeled vial dose (50 mg) when 10 mL is withdrawn from the vial.
Caspofungin Accord er ikke undersøgt hos gravide kvinder.
Caspofungin Accord has not been studied in pregnant women.
Caspofungin Accord koncentrat til infusionsvæske, opløsning, er et hvidt til offwhite pulver.
Caspofungin Accord powder for concentrate for solution for infusion is a white to off-white powder.
Caspofungin er i in vitro undersøgelser negativ med henblik på genotoksicitet, såvel som i in vivo undersøgelser med knoglemarvskromosom hos mus.
Caspofungin was negative in in vitro assays for potential genotoxicity as well as in the in vivo mouse bone marrow chromosomal test.
Caspofungin er ikke et substrat for P-glycoprotein og er et dårligt substrat for cytokrom P450 enzymer.
Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for cytochrome P450 enzymes.
Caspofungin er ikke et substrat for P-glycoprotein, og er et dårligt substrat for cytokrom P450 enzymer.
Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for cytochrome P450 enzymes.
Caspofungin er ikke substrat for P-glykoprotein, og er et dårligt substrat for CYP-enzymer.
Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for cytochrome P450 enzymes.
Caspofungin havde ingen indvirkning på farmakokinetikken for amphotericin B, itraconazol, rifampicin eller mycophenolat mofetil.
Caspofungin did not influence the pharmacokinetics of amphotericin B, itraconazole, rifampicin or mycophenolate mofetil.
Caspofungins sikkerhed og effekt blev vurderet hos børn i alderen 3 måneder til 17 år i to prospektive, kliniske multicenterundersøgelser.
The safety and efficacy of caspofungin was evaluated in paediatric patients 3 months to 17 years of age in two prospective, multicenter clinical trials.
Castleford, West Yorkshire, WF10 5HX Storbritannien
Castleford, West Yorkshire, WF10 5HX United Kingdom
Castleford, West Yorkshire, WF10 5HX Storbritannien
Ridings Point, Whistler Drive Castleford, West Yorkshire, WF10 5HX United Kingdom
Castletroy Limerick Irland
Castletroy Limerick Ireland
Catumaxomab binder sig også til et tredje stof kaldet Fc- gammareceptoren, som også hjælper kroppens immunsystem med at angribe kræftcellerne.
Catumaxomab also attaches to a third substance called the Fc-gamma receptor, which also helps the body’s immune system to target the cancer cells.
Catumaxomab blev administreret som fire intraperitoneale infusioner ved konstant hastighed over 3 timer i doser på 10, 20, 50 og 150 mikrogram på henholdsvis dag 0, 3, 7 og 10, i begge grupper.
Catumaxomab was administered as four 3-hour constant-rate i.p. infusions in doses of 10, 20, 50 and 150 micrograms on day 0, 3, 7 and 10, respectively, in both groups.
Catumaxomabs in vivo anti- tumoraktivitet blev bekræftet i en immunologisk kompromitteret musemodel med ovariekarcinom, hvor tumorudviklingen blev forsinket af en intraperitoneal behandling med catumaxomab og humane mononukleære celler i perifert blod.
The in vivo anti-tumour activity of catumaxomab was confirmed in an immunologically compromised mouse model of ovarian carcinoma, where tumour development was delayed by an intraperitoneal treatment with catumaxomab and human peripheral blood mononuclear cells.
Cav = den gennemsnitlige koncentration målt ved steady-state
Cav = the average concentration when measured at steady state
Cav kvartilanalyser af pivotale patientstudier med posaconazol tablet og oral suspension
Cav quartile analyses of pivotal patient studies with posaconazole tablet and oral suspension
Caxton Road, Bedford, Bedfordshire, MK41 0XZ Storbritannien
Caxton Road, Bedford, Bedfordshire, MK41 0XZ United Kingdom
Cayston 75 mg pulver og solvens til opløsning til nebulisator
Cayston 75 mg powder and solvent for nebuliser solution
Cayston blev sammenlignet med TNS i løbet af tre 28-dages behandlingsforløb i et randomiseret, aktivt kontrolleret, multicenterstudie (GS-US-205-0110).
Cayston was compared to TNS over three 28-day courses of treatment in a randomised, active- controlled, multicenter study (GS-US-205-0110).
Cayston blev vurderet over en periode på 28 dages behandling (ét behandlingsforløb) i to randomiserede, dobbeltblinde, placebokontrollerede multicenterstudier (CP-AI-005 and CP-AI-007).
Cayston was evaluated over a period of 28-days of treatment (one course) in two randomised, double- blind, placebo-controlled, multicentre studies (CP-AI-005 and CP-AI-007).
Cayston HÆTTEGLAS ETIKET
Cayston VIAL LABEL
Cayston leveres i et 2 ml ravfarvet hætteglas med en grå gummiprop og aluminiumsforsegling til afrivning med eller uden et blåt låg.
Cayston is contained in a 2 ml amber glass vial with a grey rubber stopper and aluminium tear-off overseal with or without a blue cap.
Cayston må ikke blandes med anden medicin i Altera-forstøveren.
Do not mix Cayston with any other medicines in the Altera Nebuliser Handset.
Cayston var mere effektivt end placebo til supprimering af lungeinfektion forårsaget af P. aeruginosa- bakterier hos patienter med cystisk fibrose.
Cayston was more effective than placebo at suppressing lung infection caused by P. aeruginosa bacteria in patients with cystic fibrosis.
CBP15+-arm: Fem serier af Avastin (15 mg/kg hver 3. uge startende i serie 2) i kombination med carboplatin (AUC 6) og paclitaxel (175 mg/m2) i 6 serier, efterfulgt af fortsat behandling med Avastin (15 mg/kg hver 3. uge) som monoterapi, i op til sammenlagt 15 måneders behandling.
CPB15+ arm: Five cycles of Avastin (15 mg/kg q3w started cycle 2) in combination with carboplatin (AUC 6) and paclitaxel (175 mg/m2) for 6 cycles followed by continued use of Avastin (15 mg/kg q3w) as single agent for a total of up to 15 months of therapy.
CBRe % patienter
CBRe % of patients
CC blev defineret som ingen opkastning og/eller opkastningsfornemmelser, ikke mere end let kvalme og ingen nødmedicin fra den første administration indtil 24 timer efter starten på den sidste dags administration af flerdags kemoterapi.
CC was defined as no vomiting and/or retching, no more than mild nausea and no rescue medicine from the first administration until 24 hours after the start of the last day’s administration of multi-day chemotherapy.
cCCyRa 80,3%
cCCyRa 80.3
cCCyRb 88,0%
CCyRb 88.0
CCID50 - Den mængde virus som inficerer 50 % af de inokulerede cellekulturer
CCID50 – the quantity of virus, which infects 50 % of the cell cultures inoculated.
CCID50 - Den mængde virus som inficerer 50 % af de inokulerede cellekulturer.
CCID50 – the quantity of virus, which infects 50 % of the cell cultures inoculated.
CCID50 pr. dosis
CCID50 per dose
CCID50*
Administration
CCID50*
period
CCID50*
Polyproylene
CCID50: Cell Culture Infective Dose 50%
CCID50 : Cell Culture Infective Dose 50
CCR5-antagonist
Antibiotics
CCR5-antagonist
CCR5 antagonist
CCR5-antagonist
Saquinavir/ritonavir/Efavirenz
CCR5-antagonister
CCR5 antagonist
CCR5-HÆMMER
CCR5 ANTAGONIST
CCR5-hæmmere
CCR5 Antagonists
CCR5-hæmmere
CCR5 inhibitors
CCR5-receptorantagonist
CCR5 receptor antagonist
CCR5-receptorantagonister
CCR5 Receptor Antagonists
CCyR (95% KI)
CCyR (95% CI)
CCyR, % (95 % CI)
CCyR, % (95% CI)
CCyR, % (95 % CI)
MMRd, % (95% CI)
CCyR-rate ved 24 måneder (inkluderer patienter, der opnåede CCyR ved eller før 24 måneders- tidspunktet, som respondenter) var statistisk signifikant højere for både gruppen, der fik nilotinib 300 mg 2 gange dagligt, og gruppen, der fik nilotinib 400 mg 2 gange dagligt, sammenlignet med gruppen, der fik imatinib 400 mg 1 gang dagligt.
CCyR rate by 24 months (includes patients who achieved CCyR at or before the 24 month time point as responders) was statistically higher for both the nilotinib 300 mg twice daily and 400 mg twice daily groups compared to the imatinib 400 mg once daily group.
CCyRb 85,3% (80,4-89,4)
CCyRb 85.3% (80.4-89.4)
CCyRb 87,3%
CCyRb 87.3
CCyRb 87,6%
CCyRb 87.6
CCyRb 88,0%
CCyRb 88.0
CD-studie I: Infliximab naive patienter
CD Study I: Infliximab Naive Patients
CD-studie II: Infliximab erfarne patienter
CD Study II: Infliximab Experienced Patients
CD-Studie II: Infliximab- erfarne patienter
CD Study II: Infliximab Experienced Patients
CD-StudieI I: Infliximab naive patienter
CDStudy I: Infliximab Naive Patients
CD-StudieI I: Infliximab-naive patienter
CDStudy I: Infliximab Naive Patients
CD19, der findes på overfladen af alle B-celler, herunder ALL-celler
CD19, which is found on the surface of all B-cells, including ALL cells;
CD20 findes på såvel normale som maligne B-celler, men ikke på hæmatopoietiske stamceller, pro-B- celler, normale plasmaceller eller andet normalt væv.
CD20 is found on both normal and malignant B cells, but not on haematopoietic stem cells, pro-B cells, normal plasma cells or other normal tissue.
CD20+ follikulær lymfom grad 1 eller 2, stadium III eller IV på diagnosetidspunktet, normale perifere blodcelletal, < 25 % involvering af knoglemarven, alder ≥ 18 år, komplet respons (CR/Cru) eller partiel respons (PR) efter 1. linjebehandling med kemoterapi bedømt ved en objektiv undersøgelse, CT-scanning og knoglemarvsbiopsi.
CD20+ grade 1 or 2 follicular lymphoma; stage III or IV at diagnosis; normal peripheral blood cell counts; < 25% bone marrow involvement; age ≥ 18 yrs; and complete response (CR/Cru) or partial response (PR) after first-line chemotherapy determined by physical examination, CT scans and bone marrow biopsy.